-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Editor | xi Obesity is an emerging global health threat that affects people of all ages
.
Being overweight, especially obesity, puts people at higher risk for life-threatening diseases such as heart attack, stroke, diabetes and cancer
.
About 20-30% of the population in Hong Kong itself is overweight or obese
.
The most effective way to deal with obesity is to reduce food intake, but people with obesity have difficulty adjusting their eating habits due to loss of satiety
.
Discovering a factor that specifically controls weight and studying how it regulates satiety after eating is critical for developing treatments for obesity
.
On February 17, 2022, a research team led by Dr.
Wang Kailiang, Assistant Professor of the Teaching and Research Department of Hong Kong Institute of Chinese Medicine, and Professor Bian Zhaoxiang, Professor of Clinical Research of Tsang Zhaotian, Director of the Clinical Department and Hong Kong TCM Clinical Research Center, published the article Body weight on Nature Metabolism regulation via MT1-MMP-mediated cleavage of GFRAL, discovered a mechanism by which a proteolytic enzyme called membrane-type matrix metalloproteinase (MT1-MMP) regulates the satiety signal of the brain in response to a fatty diet
.
The team created a mouse model of obesity by feeding mice a diet rich in fat (45%), mimicking the overweight condition in humans
.
Obese mice show increased MT1-MMP activity in the Area Postrema and Nucleus of the Solitary Tract, brain regions involved in appetite and weight regulation
.
They further found that MT1-MMP snips the receptor for the satiety hormone GDF15, called GFRAL, from the surface of brain neurons, preventing GDF15 from binding to it, which in turn shields the neurons from the appetite-suppressing satiety signals from GDF15
.
These data suggest that increased MT1-MMP activity in the brains of obese mice may be a risk factor for persistent weight gain in the context of obesity
.
To explore the potential of targeting MT1-MMP to treat obesity, they employed genetic and pharmacological interventions to inhibit MT1-MMP activity in vivo
.
They found that a transgenic mouse model targeting MT1-MMP knockout in satiety neurons was resistant to high-fat diet-induced obesity
.
Likewise, pharmacological intervention of MT1-MMP by using specific neutralizing antibodies, in various mouse models of obesity (including high-fat diet-induced obese mice and spontaneously obese mice), including food intake, glucose Metabolic parameters including tolerance and body weight were significantly improved
.
This study provides a revolutionary new strategy for the development of innovative drugs for obesity and related diseases
.
The collaborative research team includes Prof.
Zhongjun Zhou from the Faculty of Biomedical Sciences, The University of Hong Kong, Dr.
Baiqin Ye from the Faculty of Biomedical Sciences, The Chinese University of Hong Kong, Dr.
Xin Ge from the Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, and Prof.
Mart Saarma from the Institute of Biotechnology, University of Helsinki.
.
Original link: https://doi.
org/10.
1038/s42255-022-00529-5 Publisher: 11th Reprint Notice [Non-original article] The copyright of this article belongs to the author of the article, and you are welcome to forward and share it personally.
Reprinting is prohibited without permission.
The author has all legal rights, and violators will be prosecuted
.
